异基因造血细胞移植后复发时非选择性或白血病反应性 T 细胞的过继转移治疗。
Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.
机构信息
The Transplantation and Leukemia Service of the Department of Medicine and the Immunology and Molecular Pharmacology Programs at Memorial Sloan Kettering Cancer Center, United States.
出版信息
Semin Immunol. 2010 Jun;22(3):162-72. doi: 10.1016/j.smim.2010.02.003. Epub 2010 May 26.
Abstract
Adoptive transfer of in vivo generated antigen-specific donor-derived T-cells is increasingly recognized as an effective approach for the treatment or prevention of EBV lymphomas and cytomegalovirus infections complicating allogeneic hematopoietic cell transplants. This review examines evidence from preclinical experiments and initial clinical trials to critically assess both the potential and current limitations of adoptive transfer of donor T-cells sensitized to selected minor alloantigens of the host or to peptide epitopes of proteins, differentially expressed by clonogenic leukemia cells, such as the Wilms tumor protein, WT-1, as a strategy to treat or prevent recurrence of leukemia in the post-transplant period.
摘要
过继输注体内产生的抗原特异性供者源性 T 细胞，逐渐被认为是治疗或预防 EBV 淋巴瘤和巨细胞病毒感染的有效方法，这些并发症常发生于异基因造血细胞移植。本综述通过临床前实验和初步临床试验的证据，来批判性地评估过继输注对宿主的选择次要同种异体抗原或差异性表达于成克隆性白血病细胞的蛋白质的肽表位致敏的供者 T 细胞的潜在性和当前局限性，这种策略是作为治疗或预防移植后白血病复发的方法。
相似文献
1
Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.异基因造血细胞移植后复发时非选择性或白血病反应性 T 细胞的过继转移治疗。
Semin Immunol. 2010 Jun;22(3):162-72. doi: 10.1016/j.smim.2010.02.003. Epub 2010 May 26.
2
WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.从健康供体外周血中产生的WT1肽特异性T细胞：对异基因干细胞移植后过继性免疫治疗的潜在意义。
Leukemia. 2009 Sep;23(9):1634-42. doi: 10.1038/leu.2009.70. Epub 2009 Apr 9.
3
Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.在异基因造血干细胞移植后，阿扎胞苷和供体淋巴细胞输注诱导的WT1特异性T细胞反应产生的移植物抗白血病效应。
Cytotherapy. 2017 Apr;19(4):514-520. doi: 10.1016/j.jcyt.2016.12.007. Epub 2017 Jan 27.
4
Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.利用单倍体造血干细胞移植后供体来源的 Wilms 肿瘤抗原 1 特异性细胞毒性 T 淋巴细胞治疗儿童白血病的可行性临床前研究
Cytotherapy. 2019 Sep;21(9):958-972. doi: 10.1016/j.jcyt.2019.06.007. Epub 2019 Jul 4.
5
Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants.在异基因造血细胞移植后，采用供体类型的抗原特异性T细胞进行病毒感染的免疫治疗。
Immunol Res. 2007;38(1-3):237-50. doi: 10.1007/s12026-007-0059-2.
6
Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.增强和维持抗白血病效应而不加重移植物抗宿主病的策略。
Front Immunol. 2018 Dec 21;9:3041. doi: 10.3389/fimmu.2018.03041. eCollection 2018.
7
HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.HA-1H T 细胞受体基因转导重定向病毒特异性 T 细胞用于异基因干细胞移植后血液系统恶性肿瘤的治疗：一项 1 期临床研究。
Front Immunol. 2020 Aug 20;11:1804. doi: 10.3389/fimmu.2020.01804. eCollection 2020.
8
Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.过继性 T 细胞转移治疗异基因干细胞移植后难治性病毒感染的策略。
J Hematol Oncol. 2019 Feb 6;12(1):13. doi: 10.1186/s13045-019-0701-1.
9
Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies.异基因造血干细胞移植后白血病复发的控制：将移植与基因改造的T细胞疗法相结合。
Curr Opin Hematol. 2015 Nov;22(6):489-96. doi: 10.1097/MOH.0000000000000177.
10
New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.异基因干细胞移植的新策略：使用辐照后的异基因T细胞进行免疫治疗。
Bone Marrow Transplant. 2000 May;25 Suppl 2:S20-4. doi: 10.1038/sj.bmt.1702347.
引用本文的文献
1
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.WT1 致敏自体 T 细胞治疗复发性卵巢癌的 I 期剂量递增安全性和可行性研究。
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002752.
2
Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform.利用高通量遗传平台鉴定 T 细胞受体治疗药物的靶标和细胞。
Cancer Immunol Res. 2020 May;8(5):672-684. doi: 10.1158/2326-6066.CIR-19-0745. Epub 2020 Mar 17.
3
Recent advances in T-cell immunotherapy for haematological malignancies.血液系统恶性肿瘤T细胞免疫疗法的最新进展
Br J Haematol. 2017 Mar;176(5):688-704. doi: 10.1111/bjh.14470. Epub 2016 Nov 29.
4
HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.HLA-DPB1 错配等位基因是异基因造血干细胞移植后 CD4 T 细胞免疫治疗中强有力的白血病排斥抗原。
Leukemia. 2017 Feb;31(2):434-445. doi: 10.1038/leu.2016.210. Epub 2016 Aug 1.
5
Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS.T细胞去除的同种异体移植物导致移植物抗宿主病（GvHD）的发生率较低，这有助于对急性髓系白血病（AML）和骨髓增生异常综合征（MDS）移植后复发进行进一步治疗。
Bone Marrow Transplant. 2016 Jul;51(7):991-3. doi: 10.1038/bmt.2016.23. Epub 2016 Feb 29.
6
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic).用于治疗急性白血病（髓系和淋巴细胞系）的新型免疫治疗方法。
Ther Adv Hematol. 2016 Feb;7(1):17-39. doi: 10.1177/2040620715616544.
7
Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.采用体外扩增T细胞进行白血病的过继性免疫治疗。
Curr Drug Targets. 2017;18(3):271-280. doi: 10.2174/1389450117666160209143529.
8
Adoptive T-cell therapy for Leukemia.白血病的过继性T细胞疗法。
Mol Cell Ther. 2014 Aug 12;2:25. doi: 10.1186/2052-8426-2-25. eCollection 2014.
9
T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect.造血干细胞移植后血液系统恶性肿瘤的T细胞和自然杀伤细胞疗法：增强移植物抗白血病效应
Haematologica. 2015 Jun;100(6):709-19. doi: 10.3324/haematol.2014.113860.
10
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.针对威尔姆斯瘤1肽的T细胞受体样抗体的亲和力成熟极大地增强了治疗潜力。
Leukemia. 2015 Nov;29(11):2238-47. doi: 10.1038/leu.2015.125. Epub 2015 May 19.
本文引用的文献
1
T cell receptor gene therapy for cancer.T 细胞受体基因疗法治疗癌症。
Hum Gene Ther. 2009 Nov;20(11):1240-8. doi: 10.1089/hum.2009.146.
2
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.供体T细胞的细胞毒性T淋巴细胞疗法可预防和治疗单倍体相合及匹配无关供者干细胞移植后的腺病毒和EB病毒感染。
Blood. 2009 Nov 5;114(19):4283-92. doi: 10.1182/blood-2009-07-232454. Epub 2009 Aug 21.
3
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.在来自匹配无关供者的造血细胞移植中使用或不使用抗T细胞球蛋白进行标准移植物抗宿主病预防：一项随机、开放标签、多中心3期试验。
Lancet Oncol. 2009 Sep;10(9):855-64. doi: 10.1016/S1470-2045(09)70225-6. Epub 2009 Aug 18.
4
Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.为临床试验开发一种 Wilms 瘤抗原特异性 T 细胞受体：工程化患者的 T 细胞可在 NOD/SCID 小鼠中消除自体白血病母细胞。
Haematologica. 2010 Jan;95(1):126-34. doi: 10.3324/haematol.2009.006486. Epub 2009 Aug 13.
5
Safety and immunologic effects of IL-15 administration in nonhuman primates.白细胞介素-15在非人灵长类动物中的安全性及免疫效应
Blood. 2009 Sep 17;114(12):2417-26. doi: 10.1182/blood-2008-12-189266. Epub 2009 Jul 15.
6
HLA-A disparities illustrate challenges for ranking the impact of HLA mismatches on bone marrow transplant outcomes in the United States.人类白细胞抗原A（HLA-A）的差异表明，在美国，要对HLA错配在骨髓移植结果中的影响进行排名面临挑战。
Biol Blood Marrow Transplant. 2009 Aug;15(8):971-81. doi: 10.1016/j.bbmt.2009.04.015.
7
WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance.慢性髓性白血病患者外周血白细胞中的WT1表达可用于预测伊马替尼耐药性。
Neoplasma. 2009;56(5):393-7. doi: 10.4149/neo_2009_05_393.
8
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.一项针对急性髓系白血病（AML）和骨髓增生异常综合征（MDS）患者的肾母细胞瘤基因产物1（WT1）肽疫苗接种的临床和免疫2期试验。
Blood. 2009 Jun 25;113(26):6541-8. doi: 10.1182/blood-2009-02-202598. Epub 2009 Apr 23.
9
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.程序性死亡受体1（PD-1）是黑色素瘤患者中NY-ESO-1特异性CD8 + T细胞扩增的调节因子。
J Immunol. 2009 May 1;182(9):5240-9. doi: 10.4049/jimmunol.0803245.
10
Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells.共同编程的次要组织相容性抗原反应性病毒特异性T细胞双重特异性的动力学保存
Cancer Res. 2009 Mar 1;69(5):2034-41. doi: 10.1158/0008-5472.CAN-08-2523. Epub 2009 Feb 17.
Zotero 插件